Regeneron’s COVID-19 cocktail helps prevent symptomatic disease—study
ZURICH — Regeneron’s COVID-19 antibody cocktail helped cut the risk of symptomatic infections by 81% among people in households where another member had become ill, according to a statement on Monday from its manufacturing partner, Roche.
“The subcutaneous administration of casirivimab and imdevimab reduced the risk of symptomatic infections by 81% in those who were not infected when they entered the trial,” Roche said.
“In addition, individuals treated with casirivimab and imdevimab who still experienced a symptomatic infection resolved their symptoms on average within one week, compared to three weeks with placebo,” the company said.
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
